MSLN and neoplasm: Building on these findings, this study developed a strategy utilizing MSLN/CD3 bsAb to activate and recruit specific subsets of NKT or Vγ9Vδ2 T cells, thereby effectively identifying and eliminating MSLN-positive tumor cells.